 PALO ALTO, Calif., Jan. 04, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO today announced that leading proxy advisory firm Institutional Shareholder Services ISS recommends that BridgeBio stockholders and Eidos Therapeutics, Inc. Nasdaq: EIDX stockholders vote FOR BridgeBios proposed merger with Eidos and each of the other proposals to be considered at both companies virtual special meetings to be held on January 19, 2021. 